B.More is a 501(c)(3) non-profit lifescience company studying psilocybin, a classic psychedelic, to treat patients suffering from Alcohol Use Disorder (AUD) and who may have been unsuccessful with more traditional drug and treatment programs.
New York University (NYU) School of Medicine, one of the nation’s premier academic medical centers, has newly created the NYU Langone Center for Psychedelic Medicine, which conducts trials focusing on substance abuse disorder research. NYU Langone Health Psychiatrist, Dr. Michael Bogenschutz and his capable clinical team are the Lead site for the B.More Phase 2 AUD study using Psilocybin.
Emmes is a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation.
Founded in 1977, Emmes has conducted over 2000 clinical studies across a broad range of therapeutic areas, with significant expertise in neurology and the management of studies using schedule 1 drugs. Emmes manages B.More’s Phase 2 AUD study with site support, enrollment, statistical programming, data management and site management/monitoring, and analysis.
Usona Institute is a non-profit medical research organization dedicated to supporting and conducting pre-clinical and clinical research to understand further the therapeutic effects of psilocybin and other consciousness-expanding medicines. Their focus is on alleviating depression in people whose current medical treatments fall short in offering relief and a better quality of life.
Usona has manufactured pharmaceutical-grade psilocybin and is currently conducting the necessary comprehensive pre-clinical toxicology work for prescription medication, enabling B.More’s FDA clinical trials
The Heffter Research Institute promotes the highest-quality scientific research with classic hallucinogens and related compounds (sometimes called psychedelics) to better understand how the mind improves the human condition and alleviates suffering.
B.More seeks to take academic research Heffter has been instrumental in developing at elite universities and pivot it into prescription medication development trials required by FDA.